Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases ; volume:20 ; number:1 ; day:13 ; month:8 ; year:2022 ; pages:1-8 ; date:12.2022
Pediatric rheumatology ; 20, Heft 1 (13.8.2022), 1-8, 12.2022
- Creator
-
Udaondo, Clara
Cámara, Carmen
Miguel Berenguel, Laura
Alcobendas Rueda, Rosa
Muñoz Gómez, Celia
Millán Longo, Claudia
Díaz – Delgado, Blanca
Falces-Romero, Iker
Díaz Almirón, Mariana
Ochando, Jordi
Méndez – Echevarría, Ana
Remesal Camba, Agustín
Calvo, Cristina
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-022-00724-4
- URN
-
urn:nbn:de:101:1-2022102910482311145469
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Udaondo, Clara
- Cámara, Carmen
- Miguel Berenguel, Laura
- Alcobendas Rueda, Rosa
- Muñoz Gómez, Celia
- Millán Longo, Claudia
- Díaz – Delgado, Blanca
- Falces-Romero, Iker
- Díaz Almirón, Mariana
- Ochando, Jordi
- Méndez – Echevarría, Ana
- Remesal Camba, Agustín
- Calvo, Cristina
- SpringerLink (Online service)
Other Objects (12)
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?